Cardiology/Vascular Diseases | Preclinical Developments

Vivasc Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vivasc Therapeutics Receives NIH Phase I STTR Grant to Utilize Novel Cardiac Targeting Peptides for Targeted Delivery of Amiodarone

Lead Product(s): CTP-Amio

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: National Institute of Health

Deal Size: $0.3 million Upfront Cash: Undisclosed

Deal Type: Funding July 15, 2020

Details:

This Phase I STTR award will accelerate the development of CTP-amio and will set the stage for larger animal model studies and full pharmacology/toxicity studies of CTP-amio in preparation for filing an Investigational New Drug application for a Phase I clinical trial.

Nyrada

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Nyrada Reveals Encouraging Cholesterol-Lowering Drug Study Results

Lead Product(s): NYX-PCSK9i

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2020

Details:

According to pre-clinical results, the cells showed an increase in LDL receptor levels and demonstrated equivalency to marketed monoclonal PCSK9 antibody drugs, evolocumab and alirocumab.

Verve Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease

Lead Product(s): Gene-editing therapies

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: ARCH Venture Partners

Deal Size: $63.0 million Upfront Cash: Undisclosed

Deal Type: Series A2 Financing June 11, 2020

Details:

The company will use the financing to advance its lead program through IND-enabling studies and fuel follow-on pipeline programs.

Primary Peptides

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Qingdao Primedicine Pharmaceutical Co. Ltd and Primary Peptides Inc. Announce Exclusive China Partnership

Lead Product(s): PP-002

Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-002

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Qingdao Primedicine Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 19, 2020

Details:

Under the terms of the Partnership, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.

Tenaya Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy

Lead Product(s): AAV-Gene Therapy

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

Details:

Three posters illustrate advances made with Tenaya's Cellular Regeneration platform using direct reprogramming of resident cardiac fibroblasts to create new cardiomyocytes.

Primary Peptides

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Simcere Pharmaceutical Group and Primary Peptides Inc. Announce Exclusive China Partnership

Lead Product(s): PP-001

Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-001

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Simcere Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 11, 2020

Details:

Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets.

BioCardia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BioCardia Announces Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure

Lead Product(s): Neurokinin 1 receptor positive mesenchymal stem cell

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

Animal research findings show substantial improvements in heart function for heart failure subjects treated with BioCardia's allogeneic neurokinin 1 receptor positive mesenchymal stem cell, CardiALLOTM.

Inositec AG

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Inositec’s INS-3001 Reduces Cardiovascular Calcification

Lead Product(s): INS-3001

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2020

Details:

INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies.

Corvidia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Corvidia Therapeutics Announces Publication in Science Translational Medicine of Strategy for Lowering Triglycerides Using a Mimetic Peptide

Lead Product(s): D6PV

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Early preclinical studies show peptide D6PV has the ability to activate the enzyme called Lipo-Protein Lipase (LPL), rapidly (within 1 -3 hours) reducing the number of triglycerides in the bloodstream

Revive Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusi...

Lead Product(s): Cannabidiol

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 20, 2020

Details:

Revive is expanding its product pipeline by leveraging its FDA orphan drug designation for cannabidiol in the prevention of ischemia and reperfusion injury from organ transplantation.

Find

Find Drugs for Cardiology/Vascular Diseases in Preclinical Development

Preclinical

Product Type

Companies

Vivasc Therapeutics

Vivasc Therapeutics Receives NIH Phase I STTR Grant to Utilize Novel Cardiac Targeting Peptides for Targeted Delivery of Amiodarone

Nyrada

Nyrada Reveals Encouraging Cholesterol-Lowering Drug Study Results

Verve Therapeutics

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease

Primary Peptides

Qingdao Primedicine Pharmaceutical Co. Ltd and Primary Peptides Inc. Announce Exclusive China Partnership

Tenaya Therapeutics

Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy

Primary Peptides

Simcere Pharmaceutical Group and Primary Peptides Inc. Announce Exclusive China Partnership

BioCardia

BioCardia Announces Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure

Inositec AG

Inositec’s INS-3001 Reduces Cardiovascular Calcification

Corvidia Therapeutics

Corvidia Therapeutics Announces Publication in Science Translational Medicine of Strategy for Lowering Triglycerides Using a Mimetic Peptide

Revive Therapeutics

Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusi...